查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
速效型胰島素的全球市場:市場規模 - 各產品，各適應症，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1159578

速效型胰島素的全球市場:市場規模 - 各產品，各適應症，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)

Rapid Acting Insulin Market Size- By Product, By Indication, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 243 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球速效型胰島素的市場規模，預計至2032年達到118億5,000萬美元，以4.90％的年複合成長率成長。

由於病毒感染和環境要素，維他命D不足，其他的環境變量等第一型糖尿病持續增加，是提高全球速效型胰島素必要性的要素。嬰幼兒的新生兒黃疸病例增加和診斷工具的進步，也成為要素。老年人口增加，隨著年齡糖尿病的風險高漲，促進市場擴大。

本報告提供全球速效型胰島素市場相關調查，市場動態，市場變數及預測，各產品、適應症、流通管道、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球速效型胰島素市場上COVID-19的影響

第5章 市場變數及預測

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球速效型胰島素市場:各產品，2019年～2032年(100萬美元)

  • Lispro胰島素
  • Aspart胰島素
  • Glulisine胰島素

第7章 全球速效型胰島素市場:各適應症，2019年～2032年(100萬美元)

  • 第一型糖尿病
  • 第二型糖尿病

第8章 全球速效型胰島素市場:各流通管道，2019年～2032年(100萬美元)

  • 醫院藥局
  • 藥妝店、零售藥局
  • 網路商店

第9章 全球速效型胰島素市場:各地區，2019年～2032年(100萬美元)

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • Adocia
    • 企業概要
    • 財務預測
    • 產品概要
    • 最近的開發
  • Biocon Limited
  • Eli Lilly
  • Gan & Lee Pharmaceuticals Co. Ltd.
  • Geropharm
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhardt Ltd.
簡介目錄
Product Code: PHAR2210

Global Rapid Acting Insulin Market Overview:

According to SPER Market Research, the Rapid Acting Insulin Market is estimated to reach USD 11.85 billion by 2032 with a CAGR of 4.90%.

Rapid acting insulin is a drug that diabetic individuals use to manage their blood sugar levels. It can be inhaled or given intravenously via an insulin pump, prefilled pen, syringe, or other devices. It is given before meals and snacks to lower abnormally high blood sugar levels and boost the amount of bolus insulin. Currently, persons who are unable to reach their postprandial glycemic goals with existing bolus insulins are thought to benefit from new insulin formulations including innovative ultra-fast-acting insulins that improve absorption.

Another reason driving the need for rapid acting insulins throughout the world is the rising prevalence of type-1 diabetes as a result of exposure to viruses and other environmental causes, poor vitamin D levels, and other environmental variables. This is also explained by the rise in neonatal jaundice cases in infants and the advancement of diagnostic tools. Additionally, the growing global elderly population is promoting market expansion since the risk of having diabetes rises with age. Leading market competitors are also producing ready-to-use kits of rapid acting insulin that are quick to administer, offered in vials and pens, and that improve glycemic control in both adults and children. These firms are also concentrating on mergers and acquisitions (M&A), which is projected to aid in the creation of new product versions for the next generation.

Increased investment in research and development (R&D) for human recombinant insulin is anticipated to drive the demand for insulin used in the management of diabetes, thereby boosting the market's growth. The global market for rapid acting insulin is primarily driven by the rise in the prevalence of diabetes on a global scale. Furthermore, because overweight or obese, an unhealthy diet, and physical inactivity, account for nearly 80% of the rise in the incidence of diabetes, sedentary and unhealthy lifestyles double the risk of developing the disease. However, the industry's expansion may be hampered by consumers' hesitation to use quick acting insulin because of adverse effects including hypoglycemia. On the other hand, emerging nations are predicted to provide attractive development prospects for the market for quick acting insulin because of their unexplored markets and undiagnosed population.

Impact of COVID-19 on the Global Rapid Acting Insulin Market

The COVID-19 epidemic, which originated in Wuhan, China, has now spread far over the world. The epidemic is being dealt with by almost all countries. In addition, due to the lockdown scenario imposed by the governments of several nations, the majority of markets have seen a decline. However, it is anticipated that the COVID-19 epidemic would help open up new development potential for businesses involved in the treatment and management of chronic illnesses. Diabetes increases the risk of significant COVID-19 problems, according to a 2020 article by the American Diabetes Association. Additionally, having diabetes together with heart disease or other issues raises the risk of developing significant COVID-19 illness since many illnesses impair a patient's ability to fight the infection. This aided important actors in adopting a variety of tactics to capture the largest possible proportion of the COVID-19 epidemic.

Patients with coronavirus illness (COVID-19) may have an increase in mortality and severity due to diabetes mellitus (DM) and poorly managed blood sugar. This is one of the primary drivers behind the demand for fast-acting insulins to track blood glucose levels.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Product, By Indication, By Distribution Channel

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Adocia, Biocon Limited, Eli Lilly, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., Wockhardt Ltd.

Global Rapid Acting Insulin Market Segmentation:

By Product: Based on the Product, Global Rapid Acting Insulin Market is segmented as; Lispro Insulin, Aspart Insulin, Glulisine Insulin.

By Indication: Based on the Indication, Global Rapid Acting Insulin Market is segmented as; Type 1 Diabetes and Type 2 Diabetes.

By Distribution Channel: Based on the Distribution Channel, Global Rapid Acting Insulin Market is segmented as;

Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores.

By Region: The region's rapid acting insulin market was primarily driven by North America and it is predicted that the region would continue to dominate the market as a result of rising diabetes occurrences and an aging population. On the other hand, Asia-Pacific is anticipated to see the greatest growth in the market for quick acting insulin in the coming years due to the spread of obesity and westernised living habits. Over the course of the projection, this is anticipated to drive up demand for quick acting insulin.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Rapid Acting Insulin Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Rapid Acting Insulin Market, By Product, 2019-2032 (USD Million)

  • 6.1 Lispro Insulin
  • 6.2 Aspart Insulin
  • 6.3 Glulisine Insulin

7. Global Rapid Acting Insulin Market, By Indication, 2019-2032 (USD Million)

  • 7.1 Type 1 Diabetes
  • 7.2 Type 2 Diabetes

8. Global Rapid Acting Insulin Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1 Hospital Pharmacies
  • 8.2 Drug Stores and Retail Pharmacies
  • 8.3 Online Stores

9. Global Rapid Acting Insulin Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Adocia
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Biocon Limited
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 Eli Lilly
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 Gan & Lee Pharmaceuticals Co. Ltd.
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Geropharm
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 MannKind Corporation
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Merck & Co. Inc.
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 Novo Nordisk A/S
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 Sanofi S.A.
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Wockhardt Ltd.
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments